Sorrento Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 949
- Market Cap
- -
Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT04885972
- Locations
- 🇺🇸
HD Research LLC, Carrollton, Texas, United States
🇺🇸Horizon Clinical Research, La Mesa, California, United States
🇺🇸Advance Pain, Edgewood, Kentucky, United States
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04809012
Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04771351
- Locations
- 🇺🇸
Teradan Clinical Trials, Brandon, Florida, United States
Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04738175
Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04734860
- Locations
- 🇺🇸
Synergy Healthcare LLC, Bradenton, Florida, United States
🇺🇸Med-Care Research, Miami, Florida, United States
🇺🇸Collaborative NeuroScience Research, LLC, Garden Grove, California, United States
Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04728698
- Locations
- 🇺🇸
Fresno Community Hospital, Fresno, California, United States
Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-02-12
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04584697
Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04572776
Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT04559412
- Locations
- 🇺🇸
Atlanta Research Center for Rheumatology, Atlanta, Georgia, United States
Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 396
- Registration Number
- NCT04528667
- Locations
- 🇧🇷
Hospital e Maternidade Christovão da Gama, Santo André, SP, Brazil
© Copyright 2024. All Rights Reserved by MedPath